Oncology Tube· @oncologytube · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Big news in KRAS G12D NSCLC!
Can zoldonrasib (RMC-9805) finally deliver a breakthrough for this hard-to-treat mutation?
VIDEO:
https://
oncologytube.com/can-zoldonrasi
b-redefine-treatment-for-kras-g12d-nsclc-phase-1-results/
…
Dr. Jonathan W. Riess
@UCD_Cancer
presents updated Phase 1 data at #AACR26:
52% confirmed ORR
93% DCR
11.1
Heat 13 · 9 likes · 1 reply · 3 reposts
Source: Oncology Tube · x.com